AU2019269318A1 - Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function - Google Patents

Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function Download PDF

Info

Publication number
AU2019269318A1
AU2019269318A1 AU2019269318A AU2019269318A AU2019269318A1 AU 2019269318 A1 AU2019269318 A1 AU 2019269318A1 AU 2019269318 A AU2019269318 A AU 2019269318A AU 2019269318 A AU2019269318 A AU 2019269318A AU 2019269318 A1 AU2019269318 A1 AU 2019269318A1
Authority
AU
Australia
Prior art keywords
cells
cell
arid5b
population
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019269318A
Other languages
English (en)
Inventor
Frank Martin Cichocki
Jeffrey Steven Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU2019269318A1 publication Critical patent/AU2019269318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2019269318A 2018-05-14 2019-05-08 Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function Abandoned AU2019269318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670962P 2018-05-14 2018-05-14
US62/670,962 2018-05-14
PCT/US2019/031296 WO2019221991A1 (en) 2018-05-14 2019-05-08 Manipulating arid5b expression in immune cells to promote metabolism, survival, and function

Publications (1)

Publication Number Publication Date
AU2019269318A1 true AU2019269318A1 (en) 2021-01-07

Family

ID=68540927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019269318A Abandoned AU2019269318A1 (en) 2018-05-14 2019-05-08 Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function

Country Status (7)

Country Link
US (1) US12109236B2 (cg-RX-API-DMAC7.html)
EP (1) EP3793574A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021523717A (cg-RX-API-DMAC7.html)
CN (1) CN112888446A (cg-RX-API-DMAC7.html)
AU (1) AU2019269318A1 (cg-RX-API-DMAC7.html)
CA (1) CA3100312A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019221991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7793517B2 (ja) * 2019-11-28 2026-01-05 アムニオティクス・アーベー ソース細胞から決定的造血細胞を生成する方法
CN111733154B (zh) * 2020-04-30 2022-11-04 和也健康科技有限公司 磁场处理的免疫细胞及其用途
KR20230042671A (ko) * 2020-05-28 2023-03-29 바이오마그네틱 솔루션스 엘엘씨 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법
EP4419541A4 (en) * 2021-10-21 2025-12-17 Univ Texas METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6448717B1 (en) 2000-07-17 2002-09-10 Micron Technology, Inc. Method and apparatuses for providing uniform electron beams from field emission displays
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP3349770A1 (en) * 2015-09-14 2018-07-25 Regents of the University of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
US20180371052A1 (en) 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
EP3452580B1 (en) 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies

Also Published As

Publication number Publication date
US20210154232A1 (en) 2021-05-27
JP2021523717A (ja) 2021-09-09
EP3793574A4 (en) 2022-03-09
EP3793574A1 (en) 2021-03-24
WO2019221991A1 (en) 2019-11-21
CN112888446A (zh) 2021-06-01
CA3100312A1 (en) 2019-11-21
US12109236B2 (en) 2024-10-08

Similar Documents

Publication Publication Date Title
Chen et al. Induction of myelodysplasia by myeloid-derived suppressor cells
Kreisel et al. Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis
Tsoi et al. Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance
US11584787B2 (en) Soluble CD33 for treating myelodysplastic syndromes (MDS)
US12109236B2 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
Sun et al. Clusterin drives myeloid bias in aged hematopoietic stem cells by regulating mitochondrial function
Jackson et al. The Haematopoietically-expressed homeobox transcription factor: roles in development, physiology and disease
WO2014111876A2 (en) Modulation of mitophagy and use thereof
Bae et al. Phc2 controls hematopoietic stem and progenitor cell mobilization from bone marrow by repressing Vcam1 expression
EP3600418A1 (en) Low-density lipoprotein receptor related protein 5 inhibition suppresses tumor formation
EP2970975A1 (en) Targeting chromatin modifiers for the treatment of medical conditions
Saka et al. Chromatin factor YY1 controls fetal hematopoietic stem cell migration and engraftment in mice
Bellantuono et al. Stem cell ageing: does it happen and can we intervene?
US20210169913A1 (en) Fcrl6 and its uses related to cancer
Won et al. A new triggering receptor expressed on myeloid cells (TREM) family member, TLT-6, is involved in activation and proliferation of macrophages
CN105473710B (zh) 同源盒转录因子VentX调控人树突状细胞的分化和成熟
HK40044945A (en) Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
Mammadli et al. Inhibition of ITK differentiates GVT and GVHD in allo-HSCT
Horwitz Uncovering key determinants of skeletal muscle repair
Rodella Svelare l'origine specifica cellulare di Oncostatina M (OSM) nel rilascio di cellule staminali ematopoietiche (HSPCs)
Arizkane Impact of tyrosine kinase inhibitors and bone morphogenetic proteins on persistent leukemic stem cell dormancy in Chronic Myeloid Leukemia patients at remission
Gao et al. Targeting CAR-T cell senescence through Mysm1-SSBP1 axis improves persistence and therapeutic efficacy
Elenbaas Characterizing the Causal Role of SVEP1 in Human Disease
Kouskoff et al. Editors' Showcase 2021: Insights in Stem Cell Research
Di Bella The PERK (s) of having your own niche: how Acute Myeloid Leukaemia transforms the Bone Marrow Microenvironment

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period